Abstract
Malignant salivary gland cancers (SGCs) are a very heterogeneous group of tumors including several disease entities that are often completely different from each other. One of the most important divergences is the histopathological picture. This may be the mirror of a different pathogenesis, and it can reflect diverse clinical behaviors. According to the World Health Organization (WHO) classification (2017), more than 20 malignant histotypes are currently identified, but for clinical purposes we can split SGCs in two big groups: adenoid cystic carcinoma (ACC) that is the most common histotype in metastatic patients (60%) and other histotypes (here defined as non-ACC). This latter group includes several histotypes rarer than ACC, such as mucoepidermoid carcinoma, salivary duct carcinoma (SDC), adenocarcinoma, not otherwise specified (NOS), myoepithelial carcinoma, etc. ACC population is typically characterized by a slow-growing and indolent evolution, while non-ACCs are more aggressive histotypes. This could explain a different clinical management of ACC in respect to non-ACC. In fact, bearing in mind that a standardized first-line treatment for advanced SGCs is far to be defined, only in ACC population a watchful waiting approach may be also considered in the absence of symptomatic and/or rapidly progressive disease. Having said that, if the start of systemic therapy is indicated, chemotherapy (cisplatin alone or in combination with other chemo agents) is the most recommended treatment, both in ACC and non-ACC groups. To date, androgen deprivation therapy (ADT) is the only effective tailored approach active in AR-expressing SDC and adenocarcinoma, NOS, and an ongoing international trial (NCT01969578) will clarify the role of ADT as frontline treatment over chemotherapy. Other targeted agents have not demonstrated till now any advantage in patients with metastatic SGCs. However, comprehensive better understanding of biology and genetics of these rare cancers could lead to identifying further druggable targets and potentially improving patient’s outcome. Notably, data on immunotherapy in SGCs are still scarce, but the ongoing studies could contribute to assess its role in these patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACC:
-
Adenoid cystic carcinoma
- ADT:
-
Androgen deprivation therapy
- AR:
-
Androgen receptor
- CAB:
-
Combined androgen blockade
- CDDP:
-
Cisplatin
- CI:
-
Confidence interval
- DFI:
-
Disease-free interval
- ECOG:
-
Eastern Cooperative Oncology Group
- EGFR:
-
Epidermal growth factor receptor
- EORTC:
-
European Organisation for Research and Treatment of Cancer
- FGFR:
-
Fibroblast growth factor receptor
- FISH:
-
Fluorescent in situ hybridization
- HDAC:
-
Histone deacetylase
- IGFR:
-
Insulin growth factor receptor
- IHC:
-
Immunohistochemistry
- IL2R:
-
Interleukin-2 receptor
- LHRH:
-
Luteinizing hormone-releasing hormone
- MEC:
-
Mucoepidermoid carcinoma
- NOS:
-
Not other specified
- ORR:
-
Overall response rate
- OS:
-
Overall survival
- PCa:
-
Prostate cancer
- PD-1:
-
Programmed death-1
- PDGFR:
-
Platelet-derived growth factor receptor
- PD-L1:
-
Programmed death-ligand 1
- PFS:
-
Progression-free survival
- RFA:
-
Radiofrequency ablation
- RT:
-
Radiotherapy
- SDC:
-
Salivary duct carcinoma
- SGC:
-
Salivary gland cancer
- TACE:
-
Trans-arterial chemoembolization
- TGF-β:
-
transforming growth factor-β
- TKI:
-
Tyrosine kinase inhibitor
- VEGF:
-
Vascular endothelial growth factor
- VEGFR:
-
Vascular endothelial growth factor receptor
References
Gao M, Hao Y, Huang MX, et al. Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg. 2013;42(8):923–8.
Ferrarotto R, Mitani Y, Diao L, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol. 2017;35(3):352–60.
Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12(8):815–24.
Girelli L, Locati L, Galeone C, et al. Lung metastasectomy in adenoid cystic cancer: is it worth it? Oral Oncol. 2017;65:114–8.
Alfieri S, Granata R, Bergamini C, et al. Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol. 2017;66:58–63.
Rodriguez CP, Martins RG, Baik C, et al. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. Head Neck. 2018;40(3):584–9.
Andersson MK, Afshari MK, Andrén Y, et al. Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling. J Natl Cancer Inst. 2017;109(9). https://doi.org/10.1093/jnci/djx017.
Sridharan V, Gjini E, Liao X, et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol Res. 2016;4(8):679–87.
Hong MH, Kim CG, Koh YW, et al. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018;40(1):55–62.
Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 2009;45(11):986–90.
Keller G, Steinmann D, Quaas A, et al. New concepts of personalized therapy in salivary gland carcinomas. Oral Oncol. 2017;68:103–13.
Cipriani NA, Blair EA, Finkle J, et al. Salivary gland secretory carcinoma with high-grade transformation, CDKN2A/B loss, distant metastasis, and lack of sustained response to crizotinib. Int J Surg Pathol. 2017;25(7):613–8.
Mukaigawa T, Hayashi R, Hashimoto K, et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol. 2016;114(1):36–43.
Cros J, Sbidian E, Hans S, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol. 2013;24(10):2624–9.
Dalin MG, Watson PA, Ho AL, et al. Androgen receptor signaling in salivary gland cancer. Cancers (Basel). 2017;9(2):17.
Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2016;38(5):724–31.
Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979–84.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Locati, L.D., Alfieri, S., Licitra, L. (2019). Systemic Therapy in Salivary Gland Carcinoma. In: Licitra, L., Locati, L. (eds) Salivary Gland Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-02958-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-02958-6_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02957-9
Online ISBN: 978-3-030-02958-6
eBook Packages: MedicineMedicine (R0)